Enbrel, Remicade Anti-TNF Class Labeling Debated By FDA Advisory Cmte.

Anti-TNF rheumatoid arthritis drug class labeling for tuberculosis risk was discussed by FDA's Arthritis Advisory Committee during an Aug. 17 safety update on Immunex' Enbrel (etanercept) and Centocor's Remicade (infliximab).

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet